PHAT
Phathom Pharmaceuticals, Inc. NASDAQ$12.01
Mkt Cap $875.8M
52w Low $2.21
60.9% of range
52w High $18.31
50d MA $11.55
200d MA $12.53
P/E (TTM)
-4.0x
EV/EBITDA
-7.1x
P/B
—
Debt/Equity
-0.0x
ROE
50.5%
P/FCF
-7.3x
RSI (14)
—
ATR (14)
—
Beta
0.61
50d MA
$11.55
200d MA
$12.53
Avg Volume
1.1M
About
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trial…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | -0.17 | -0.37 | -117.6% | 11.78 | -2.7% | -4.9% | +2.0% | — | — | — | — | — |
| Feb 26, 2026 | BMO | -0.32 | -0.16 | +49.9% | 12.32 | +5.5% | +10.1% | +1.9% | -7.0% | -10.3% | -10.2% | -14.5% | — |
| Oct 30, 2025 | BMO | -0.30 | -0.15 | +50.0% | 13.53 | +3.5% | -1.6% | +0.1% | +1.5% | -0.3% | -1.8% | +10.4% | — |
| Aug 7, 2025 | BMO | -0.76 | -0.79 | -3.9% | 8.68 | +6.1% | +8.3% | +12.2% | +18.4% | +19.6% | +20.7% | +43.2% | — |
| May 1, 2025 | BMO | -1.06 | -1.07 | -0.9% | 4.29 | -6.8% | -21.7% | -35.7% | -39.9% | -44.1% | -44.1% | +8.2% | — |
| Mar 6, 2025 | BMO | -1.29 | -0.79 | +38.8% | 6.08 | -5.3% | -3.0% | -16.8% | -27.6% | -21.2% | -17.8% | -19.9% | — |
| Nov 7, 2024 | BMO | -1.57 | -1.32 | +15.9% | 18.00 | +4.3% | +2.8% | -6.3% | -27.2% | -47.1% | -45.8% | -48.4% | — |
| Aug 8, 2024 | BMO | -1.20 | -1.25 | -4.2% | 10.81 | +6.4% | +8.7% | +8.7% | +11.3% | +12.6% | +15.1% | +62.8% | — |
| May 9, 2024 | BMO | -1.43 | -1.42 | +0.7% | 10.10 | -4.0% | -0.1% | -5.6% | -4.3% | +2.9% | +3.1% | +6.3% | — |
| Mar 7, 2024 | BMO | -0.92 | -0.80 | +13.0% | 9.73 | +7.8% | -6.6% | -8.7% | -15.1% | -16.0% | -17.8% | +14.2% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 27 | Barclays | Upgrade | Equal Weight → Overweight | — | $10.79 | $11.26 | +4.4% | -1.9% | -2.4% | +3.0% | +3.2% | +5.1% |
| Feb 27 | Guggenheim | Maintains | Buy → Buy | — | $13.56 | $13.53 | -0.2% | -7.4% | -15.5% | -18.5% | -18.4% | -20.8% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.31 | $14.43 | +8.4% | +1.8% | +3.2% | +1.4% | -0.2% | -2.0% |
| Jun 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.92 | $9.18 | +2.9% | -1.0% | +0.6% | +1.3% | +12.4% | +19.3% |
| Jun 9 | Craig-Hallum | Maintains | Buy → Buy | — | $8.92 | $9.18 | +2.9% | -1.0% | +0.6% | +1.3% | +12.4% | +19.3% |
| Jun 6 | Needham | Maintains | Buy → Buy | — | $4.69 | $4.80 | +2.3% | +90.2% | +88.3% | +91.3% | +92.8% | +113.9% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.36 | $3.38 | +0.6% | -17.9% | -23.2% | -28.6% | -28.6% | -31.8% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $3.36 | $3.38 | +0.6% | -17.9% | -23.2% | -28.6% | -28.6% | -31.8% |
| May 2 | Goldman Sachs | Maintains | Neutral → Neutral | — | $3.36 | $3.38 | +0.6% | -17.9% | -23.2% | -28.6% | -28.6% | -31.8% |
| May 2 | Craig-Hallum | Maintains | Buy → Buy | — | $3.36 | $3.38 | +0.6% | -17.9% | -23.2% | -28.6% | -28.6% | -31.8% |
Recent Filings
8-K
Phathom Pharmaceuticals, Inc. -- 8-K Filing
Phathom Pharmaceuticals reported Q1 2026 results and provided business updates on gastrointestinal disease treatments, with specific financial metrics and operational progress detailed in the filing.
Apr 30
8-K
Phathom Pharmaceuticals, Inc. -- 8-K Filing
Phathom Pharmaceuticals reported Q4 and full-year 2025 results with 2026 guidance, providing investors visibility into the GI-focused biopharmaceutical company's commercial progress and financial trajectory.
Feb 26
Data updated apr 26, 2026 7:32pm
· Source: massive.com